Healthcare
Live Price
Offline$3.78
+3.56% today
1Y Change
+47.21%
Window
Jun 27, 2025 → Jun 24, 2026
Coverage: 249 bars · Jun 27, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Eledon Pharmaceuticals, Inc. (ELDN) is a Healthcare stock with a market cap of $230.00M and listed on NASDAQ. The stock last traded around $3.78 and up 47.2% across the available one-year price window (Jun 27, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +25.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +25.3%, free cash flow -31.9% with operating margin 0.0% and ROIC -37.9%. Stock Foundry combines ELDN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ELDN
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ELDN Max Drawdown
-68.12%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ELDN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$34.5M
+60.8% YoY
Free Cash Flow
-$28.9M
-1.7% YoY
Revenue Growth
+0.0%
EPS Growth
+25.3%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -359K | -374K | -373K | -195K |
| Operating Income | -83M | -71M | -43M | -40M | -37M |
| EBITDA | -83M | -35M | -116M | -88M | -37M |
| Net Income | -46M | -36M | -117M | -88M | -35M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 23M | 21M | 5M | 56M | 85M |
| Total Assets | 238M | 177M | 89M | 93M | 171M |
| Total Liabilities | 101M | 59M | 82M | 9M | 7M |
| Shareholder Equity | 137M | 118M | 7M | 84M | 164M |
| Total Debt | 641K | 954K | 383K | 746K | 769K |
| Net Debt | -22M | -20M | -4M | -56M | -84M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
29M
-1.7% YoY
Capital Expenditures
0
Free Cash Flow
29M
-1.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-46.5%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.